Reviewer’s report

Title: Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

Version: 1 Date: 19 February 2014

Reviewer: Guy Berchem

Reviewer’s report:

This is a well written paper explaining clearly the results of a 3 arm randomized phase II study exploring the addition of 2 different dosing schedules of Axitinib to the standard Cisplatinum Pemetrexed regimen in non squamous NSCLC. The methods applied seem adequate and the data (although negative) seems sound. The manuscript clearly adheres to relevant standards and the discussion and conclusions are well balanced. The literature seems well cited as well.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I have received educational grants for my lab research from Roche and Pfizer.